The table below shows Axsome Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$20.70M
-$43.38M
-$53.47M
-$5.82M
-$32.65M
-$27.22M
Capital expenditure
$121.00K
$338.00K
$98.00K
$71.00K
$214.00K
$30.00K
Investing cash flow
-$121.00K
-$338.00K
-$98.00K
-$71.00K
-$214.00K
-$30.00K
Dividends paid
-
-
AXSM operating cash flow (10-K history)
Axsome Therapeutics, Inc. reported operating cash flow of -$93.41M for fiscal year 2025. That is up 27.3% from -$128.41M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$21.28M (FY 2016) to -$93.41M. Figures come from the company's audited annual reports as filed with the SEC.
